These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 8500516)

  • 1. Apolipoprotein(a) polymorphism predicts the increase of Lp(a) by pravastatin in patients with familial hypercholesterolaemia treated with bile acid sequestration.
    Klausen IC; Gerdes LU; Meinertz H; Hansen FA; Faergeman O
    Eur J Clin Invest; 1993 Apr; 23(4):240-5. PubMed ID: 8500516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy.
    Ordovas JM; Lopez-Miranda J; Perez-Jimenez F; Rodriguez C; Park JS; Cole T; Schaefer EJ
    Atherosclerosis; 1995 Mar; 113(2):157-66. PubMed ID: 7605354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of pravastatin, an HMG CoA reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by their apolipoprotein composition.
    Bard JM; Parra HJ; Douste-Blazy P; Fruchart JC
    Metabolism; 1990 Mar; 39(3):269-73. PubMed ID: 2106607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia.
    Cheung MC; Austin MA; Moulin P; Wolf AC; Cryer D; Knopp RH
    Atherosclerosis; 1993 Aug; 102(1):107-19. PubMed ID: 8257447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: effect of pravastatin.
    Rodenburg J; Vissers MN; Wiegman A; Miller ER; Ridker PM; Witztum JL; Kastelein JJ; Tsimikas S
    J Am Coll Cardiol; 2006 May; 47(9):1803-10. PubMed ID: 16682304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia.
    Naoumova RP; Marais AD; Mountney J; Firth JC; Rendell NB; Taylor GW; Thompson GR
    Atherosclerosis; 1996 Jan; 119(2):203-13. PubMed ID: 8808497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of one year of treatment with pravastatin, an HMG-CoA reductase inhibitor, on lipoprotein a.
    Hunninghake DB; Stein EA; Mellies MJ
    J Clin Pharmacol; 1993 Jun; 33(6):574-80. PubMed ID: 8366183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolaemia.
    Heath KE; Gudnason V; Humphries SE; Seed M
    Atherosclerosis; 1999 Mar; 143(1):41-54. PubMed ID: 10208479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipoprotein Lp(a) in homozygous familial hypercholesterolemia: density profile, particle heterogeneity and apolipoprotein(a) phenotype.
    Guo HC; Chapman MJ; Bruckert E; Farriaux JP; De Gennes JL
    Atherosclerosis; 1991 Jan; 86(1):69-83. PubMed ID: 1829609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pravastatin increases the activity pf the LDL receptors in lymphocytes of individuals with heterozygous familial hypercholesterolemia].
    Alvarez-Sala LA; Mata P; Blázquez E; Garrido JA; Ordovás JM; Rubio MJ; de Oya M
    Rev Clin Esp; 1997 May; 197(5):317-22. PubMed ID: 9280964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treating hypercholesterolaemia with HMG CoA reductase inhibitors: a direct comparison of simvastatin and pravastatin.
    Lintott CJ; Scott RS; Sutherland WH; Bremer J
    Aust N Z J Med; 1993 Aug; 23(4):381-6. PubMed ID: 8240151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipoprotein(a) in homozygous familial hypercholesterolemia.
    Kraft HG; Lingenhel A; Raal FJ; Hohenegger M; Utermann G
    Arterioscler Thromb Vasc Biol; 2000 Feb; 20(2):522-8. PubMed ID: 10669652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hypercholesterolemia.
    Franceschini G; Sirtori M; Vaccarino V; Gianfranceschi G; Chiesa G; Sirtori CR
    J Lab Clin Med; 1989 Sep; 114(3):250-9. PubMed ID: 2504855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apolipoprotein E phenotypes in familial hypercholesterolaemia: importance for expression of disease and response to therapy.
    Berglund L; Wiklund O; Eggertsen G; Olofsson SO; Eriksson M; Lindén T; Bondjers G; Angelin B
    J Intern Med; 1993 Feb; 233(2):173-8. PubMed ID: 8433078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of lipoprotein(a) by LDL-apheresis using a dextran sulfate cellulose column in patients with familial hypercholesterolemia.
    Koizumi J; Koizumi I; Uno Y; Inazu A; Kajinami K; Haraki T; Yagi K; Kamon N; Miyamoto S; Takegoshi T
    Atherosclerosis; 1993 Apr; 100(1):65-74. PubMed ID: 8318064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of cholesterol-lowering on plasma membrane lipids and function.
    Lijnen P; Echevaría-Vázquez D; Petrov V
    Methods Find Exp Clin Pharmacol; 1996 Mar; 18(2):123-36. PubMed ID: 8740244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic efficacy of the HMG-CoA-reductase inhibitor pravastatin in hyperlipoproteinaemia type II.
    Saxenhofer H; Weidmann P; Riesen WF; Beretta-Piccoli C; Fragiacomo C; Wunderlin R; Noseda G
    Eur J Clin Pharmacol; 1990; 39(2):101-5. PubMed ID: 2123791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum Lp(a) concentrations are unaffected by treatment with the HMG-CoA reductase inhibitor Pravastatin: results of a 2-year investigation.
    Fieseler HG; Armstrong VW; Wieland E; Thiery J; Schütz E; Walli AK; Seidel D
    Clin Chim Acta; 1991 Dec; 204(1-3):291-300. PubMed ID: 1840246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased in vitro oxidizability of low-density lipoprotein in hypercholesterolaemic patients treated with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors.
    Kleinveld HA; Demacker PN; De Haan AF; Stalenhoef AF
    Eur J Clin Invest; 1993 May; 23(5):289-95. PubMed ID: 8354335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of CS-514 (eptastatin), an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, on serum lipid and apolipoprotein levels in heterozygous familial hypercholesterolemic patients treated by low density lipoprotein (LDL)-apheresis.
    Mabuchi H; Fujita H; Michishita I; Takeda M; Kajinami K; Koizumi J; Takeda R; Takegoshi T; Wakasugi T; Ueda K
    Atherosclerosis; 1988 Aug; 72(2-3):183-8. PubMed ID: 3145745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.